AC-201

AC-201, an oral selective TYK2/JAK1 inhibitor, met its primary endpoint with up to 74.3% of patients achieving PASI-75 responses at week 12 across all three dosing regimens tested.

Accropeutics has closed a $12 million Series B+ financing round led by Shenzhen Capital Group, with participation from existing and new investors, extending its cash runway into the second half of 2026.

Accropeutics' AC-101, a RIPK2 inhibitor, received FDA clearance for a Phase II clinical trial to treat moderate-to-severe Ulcerative Colitis (UC).